These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 24027196)

  • 1. Androgen receptor signaling regulates DNA repair in prostate cancers.
    Polkinghorn WR; Parker JS; Lee MX; Kass EM; Spratt DE; Iaquinta PJ; Arora VK; Yen WF; Cai L; Zheng D; Carver BS; Chen Y; Watson PA; Shah NP; Fujisawa S; Goglia AG; Gopalan A; Hieronymus H; Wongvipat J; Scardino PT; Zelefsky MJ; Jasin M; Chaudhuri J; Powell SN; Sawyers CL
    Cancer Discov; 2013 Nov; 3(11):1245-53. PubMed ID: 24027196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
    Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
    PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.
    Bartek J; Mistrik M; Bartkova J
    Cancer Discov; 2013 Nov; 3(11):1222-4. PubMed ID: 24203954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption.
    Allen SG; Zhang C; Malone S; Roy S; Dess RT; Jackson WC; Mehra R; Speers C; Chinnaiyan AM; Sun Y; Spratt DE
    World J Urol; 2023 Dec; 41(12):3877-3887. PubMed ID: 37851053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hormone-DNA repair circuit governs the response to genotoxic insult.
    Goodwin JF; Schiewer MJ; Dean JL; Schrecengost RS; de Leeuw R; Han S; Ma T; Den RB; Dicker AP; Feng FY; Knudsen KE
    Cancer Discov; 2013 Nov; 3(11):1254-71. PubMed ID: 24027197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
    Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
    Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
    Chellini L; Pieraccioli M; Sette C; Paronetto MP
    J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Therapeutic Target for Prostate Cancer.
    Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling.
    Hänze J; Mengen LM; Mernberger M; Tiwari DK; Plagge T; Nist A; Subtil FSB; Theiss U; Eberle F; Roth K; Lauth M; Hofmann R; Engenhart-Cabillic R; Stiewe T; Hegele A
    Radiat Oncol; 2024 Jul; 19(1):85. PubMed ID: 38956684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
    Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
    Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.